- Home
- ALNY vs CTVA Comparison
ALNY vs CTVA Comparison
Compare ALNY & CTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- CTVA
- Stock Information
- Founded
- ALNY 2002
- CTVA 2018
- Country
- ALNY United States
- CTVA United States
- Employees
- ALNY N/A
- CTVA N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- CTVA Farming/Seeds/Milling
- Sector
- ALNY Health Care
- CTVA Consumer Staples
- Exchange
- ALNY Nasdaq
- CTVA Nasdaq
- Market Cap
- ALNY 34.7B
- CTVA 41.1B
- IPO Year
- ALNY 2004
- CTVA N/A
- Fundamental
- Price
- ALNY $248.79
- CTVA $58.78
- Analyst Decision
- ALNY Buy
- CTVA Buy
- Analyst Count
- ALNY 23
- CTVA 20
- Target Price
- ALNY $298.59
- CTVA $63.72
- AVG Volume (30 Days)
- ALNY 958.7K
- CTVA 3.4M
- Earning Date
- ALNY 10-31-2024
- CTVA 11-06-2024
- Dividend Yield
- ALNY N/A
- CTVA 1.16%
- EPS Growth
- ALNY N/A
- CTVA N/A
- EPS
- ALNY N/A
- CTVA 0.98
- Revenue
- ALNY $2,094,795,000.00
- CTVA $16,637,000,000.00
- Revenue This Year
- ALNY $25.14
- CTVA $1.61
- Revenue Next Year
- ALNY $17.13
- CTVA $4.04
- P/E Ratio
- ALNY N/A
- CTVA $59.83
- Revenue Growth
- ALNY 21.54
- CTVA N/A
- 52 Week Low
- ALNY $141.98
- CTVA $43.89
- 52 Week High
- ALNY $304.39
- CTVA $63.75
- Technical
- Relative Strength Index (RSI)
- ALNY 39.68
- CTVA 50.85
- Support Level
- ALNY $229.86
- CTVA $55.18
- Resistance Level
- ALNY $271.08
- CTVA $59.54
- Average True Range (ATR)
- ALNY 9.39
- CTVA 1.47
- MACD
- ALNY -4.06
- CTVA -0.28
- Stochastic Oscillator
- ALNY 33.37
- CTVA 41.95
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.